JP2023531802A5 - - Google Patents
Info
- Publication number
- JP2023531802A5 JP2023531802A5 JP2022581463A JP2022581463A JP2023531802A5 JP 2023531802 A5 JP2023531802 A5 JP 2023531802A5 JP 2022581463 A JP2022581463 A JP 2022581463A JP 2022581463 A JP2022581463 A JP 2022581463A JP 2023531802 A5 JP2023531802 A5 JP 2023531802A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- pharmaceutical composition
- hpmc
- polymer
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046117P | 2020-06-30 | 2020-06-30 | |
| US202063046115P | 2020-06-30 | 2020-06-30 | |
| US63/046,117 | 2020-06-30 | ||
| US63/046,115 | 2020-06-30 | ||
| US202163183299P | 2021-05-03 | 2021-05-03 | |
| US202163183294P | 2021-05-03 | 2021-05-03 | |
| US63/183,299 | 2021-05-03 | ||
| US63/183,294 | 2021-05-03 | ||
| PCT/US2021/039303 WO2022005926A1 (en) | 2020-06-30 | 2021-06-28 | Modified release formulations of modified forms of trimetazidine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531802A JP2023531802A (ja) | 2023-07-25 |
| JP2023531802A5 true JP2023531802A5 (https=) | 2024-06-21 |
Family
ID=79315460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022581463A Pending JP2023531802A (ja) | 2020-06-30 | 2021-06-28 | トリメタジジンの改変形態の調節放出製剤 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4171232A4 (https=) |
| JP (1) | JP2023531802A (https=) |
| KR (1) | KR20230028535A (https=) |
| CN (1) | CN116234555A (https=) |
| AU (1) | AU2021299197A1 (https=) |
| CA (1) | CA3187827A1 (https=) |
| IL (1) | IL299544A (https=) |
| WO (1) | WO2022005926A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250035269A (ko) * | 2023-09-05 | 2025-03-12 | 주식회사 뉴캔서큐어바이오 | 트리메타지딘을 포함하는 코팅정 조성물 및 이의 제조방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101466371B (zh) * | 2006-06-09 | 2011-10-05 | 施瓦茨制药有限公司 | 含非索罗定的稳定的药用组合物 |
| PE20080669A1 (es) * | 2006-09-08 | 2008-07-18 | Drugtech Corp | Composicion de liberacion sostenida que comprende levodopa |
| ITFI20130184A1 (it) * | 2013-08-01 | 2015-02-02 | Valpharma Internat S P A | Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione. |
| NZ745921A (en) * | 2016-03-09 | 2021-12-24 | Nls 1 Pharma Ag | A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd) |
| IL283725B2 (en) * | 2017-06-20 | 2024-04-01 | Imbria Pharmaceuticals Inc | Compositions and methods for increasing efficiency of cardiac metabolism |
| US10980747B2 (en) * | 2017-11-27 | 2021-04-20 | Shin-Etsu Chemical Co., Ltd. | Composition for solid preparation, solid preparation, and method for producing the same |
| CN109908096A (zh) * | 2017-12-12 | 2019-06-21 | 武汉武药科技有限公司 | 一种盐酸曲美他嗪缓释片及其制备方法 |
| EP3866794B1 (en) * | 2018-10-17 | 2024-12-04 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
-
2021
- 2021-06-28 KR KR1020237003154A patent/KR20230028535A/ko active Pending
- 2021-06-28 CN CN202180051890.7A patent/CN116234555A/zh active Pending
- 2021-06-28 EP EP21832842.5A patent/EP4171232A4/en active Pending
- 2021-06-28 CA CA3187827A patent/CA3187827A1/en active Pending
- 2021-06-28 WO PCT/US2021/039303 patent/WO2022005926A1/en not_active Ceased
- 2021-06-28 IL IL299544A patent/IL299544A/en unknown
- 2021-06-28 JP JP2022581463A patent/JP2023531802A/ja active Pending
- 2021-06-28 AU AU2021299197A patent/AU2021299197A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009530415A5 (https=) | ||
| HU199302B (en) | Process for producing synergic pharmaceutical compositions having hypotensive activity | |
| JP2023531802A5 (https=) | ||
| JP2024508526A5 (https=) | ||
| JP2002527388A5 (https=) | ||
| JP2024522817A5 (https=) | ||
| JP2024083460A5 (https=) | ||
| CN1149987C (zh) | 含索他洛尔右旋和左旋异构体混合物的药物组合物 | |
| JP2010529142A5 (https=) | ||
| JP2012522742A (ja) | ７−［４−［４−（２，３−ジクロロフェニル）ピペラジン−１−イル］ブトキシ］−３，４−ジヒドロ−１ｈ−キノリン−２−オン塩基またはその塩もしくは水和物を含む経口フィルム | |
| WO2005040106A1 (en) | Thiourea derivative-containing pharmaceutical composition having improved solubility and bioavailability | |
| JP2024540172A5 (https=) | ||
| CN1127336C (zh) | 肺性心病治疗剂 | |
| JP2025511126A5 (https=) | ||
| JP2022505033A (ja) | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 | |
| CN107206007A (zh) | 用于治疗肺高血压的方法 | |
| CN112716951A (zh) | 包含氨氯地平和氯沙坦的固体药物组合物 | |
| CN104093400A (zh) | 稳定的无定形雷特格韦钾盐预混料及其制备方法 | |
| CN102762199B (zh) | 包含伪麻黄碱和左西替利嗪的口服复合组合物 | |
| JP2023532330A5 (https=) | ||
| EP3368030A1 (en) | Pharmaceutical compositions of dimethyl fumarate | |
| JP4675751B2 (ja) | アムロジピンを含有する安定化された医薬品組成物 | |
| JPS61165327A (ja) | 肝疾患治療薬 | |
| JP2022515067A5 (https=) | ||
| CN1310891C (zh) | N－哌啶基－1－（2，4－二氯苯基）－4－甲基－5－（4－氯苯基）吡唑－3－甲酰胺有机酸盐及其药物组合物 |